HERA should be independent and autonomous with a clear public health mission, EPHA says

by Yannis Natsis | Feb 24, 2021 | Universal Access and Affordable Medicines | Latest Developments

EPHA’s submission to the feedback mechanism on the on the HERA (Health Emergency Preparedness and Response Authority) inception impact assessment The COVID-19 pandemic has shown that Europe has paid the price of not being prepared in the biomedical research &...

Transparency is a fundamental pillar for the success of the EU Vaccines Strategy

by Yannis Natsis | Dec 17, 2020 | COVID-19, Universal Access and Affordable Medicines | Latest Developments

39 civil society organisations including EPHA are calling on the European Commission and EU national governments to ensure a maximum degree of transparency in the EU’s exchanges, negotiations and deals with pharmaceutical companies over COVID19 vaccines, proposing a...

Putting medicines policy under the spotlight: EPHA’s #A2MDialogues

by Yannis Natsis | Nov 14, 2020 | Universal Access and Affordable Medicines | Latest Developments

Pharmaceutical policies and access to medicines top the policy agenda especially as the COVID19 challenges bring issues such as transparency in pharma, affordability of therapeutics, role of public support in biomedical innovation to the forefront. It is now more...

Best treatment for cancer patients in Europe?

by European Public Health Alliance | Nov 14, 2020 | Cancer, Universal Access and Affordable Medicines | Analysis & Opinion

Guest article | Lydie Meheus PhD, Managing Director, Belgian Anticancer FundCancer patients want to have access to the best available treatment and they want it fast, as in many cases they expect it to be lifesaving.Unfortunately, the current system to bring a new...

The European Pharmaceutical Strategy: An inventory for action for Europe

by Yannis Natsis | Nov 14, 2020 | Universal Access and Affordable Medicines | Analysis & Opinion

We have come a long way in a short period of time since the adoption of the groundbreaking June 2016 Council Conclusions on pharmaceuticals. The conclusions were a milestone for the access to medicines debate as they signaled the political acknowledgment of the series...

Recommendations for unleashing meaningful innovation through regulatory reform

by European Public Health Alliance | Nov 10, 2020 | Universal Access and Affordable Medicines | Latest Developments, Universal Access and Affordable Medicines | Publications

What do we know when a new medicine is approved? What are the regulatory requirements for new medicines? What happens once a new drug is on the market? Following the first  of the EPHA #A2MDialogues,  our panelists Andrea Cipriani, Lydia Meheus, Huseyin Naci and Beate...